Breakthrough Cancer Technology, First to Cross Blood-Brain Barrier, Fights Glioblastoma Cells Directly
www.superpowers4good.com
Only anthracycline drug engineered to attack tumor cells at the site; initial clinical testing funds expected to come from equity crowdfunding Press Release – HOUSTON, TX, April 18, 2018 – In fighting the deadliest form of brain cancer, Glioblastoma, cancer specialists have been extremely frustrated by the inability of anticancer drugs to penetrate the blood-brain barrier (BBB). Now, for the first time, a drug is being developed which has shown in clinical testing to cross this barrier and attack the tumor directly. Belonging to the class of powerful anthracyclines considered to be among the most effective anticancer treatments ever developed, Berubicin, was created in the lab of world-renowned cancer therapeutics expert Dr. Waldemar Priebe, Professor of Medicinal Chemistry at the Department of Experimental Therapeutics, at the M.D. Anderson Cancer Center. Today, CNS Pharmaceuticals is working to develop this compound, which is expected to enter Phase II Clinical Trials funded in part by an equity crowdfunding campaign.
Breakthrough Cancer Technology, First to Cross Blood-Brain Barrier, Fights Glioblastoma Cells Directly
Breakthrough Cancer Technology, First to…
Breakthrough Cancer Technology, First to Cross Blood-Brain Barrier, Fights Glioblastoma Cells Directly
Only anthracycline drug engineered to attack tumor cells at the site; initial clinical testing funds expected to come from equity crowdfunding Press Release – HOUSTON, TX, April 18, 2018 – In fighting the deadliest form of brain cancer, Glioblastoma, cancer specialists have been extremely frustrated by the inability of anticancer drugs to penetrate the blood-brain barrier (BBB). Now, for the first time, a drug is being developed which has shown in clinical testing to cross this barrier and attack the tumor directly. Belonging to the class of powerful anthracyclines considered to be among the most effective anticancer treatments ever developed, Berubicin, was created in the lab of world-renowned cancer therapeutics expert Dr. Waldemar Priebe, Professor of Medicinal Chemistry at the Department of Experimental Therapeutics, at the M.D. Anderson Cancer Center. Today, CNS Pharmaceuticals is working to develop this compound, which is expected to enter Phase II Clinical Trials funded in part by an equity crowdfunding campaign.